Tengo un vecino con dislexia en cuanto a la recogida selectiva de basura se refiere. Saca orgánica cuando toca vidrio y envases el día que toca papel. El resultado es que en la puerta del bloque siempre hay una bolsa fuera de contexto. Hay imágenes que entristecen, como un patio de colegio vacío, un zapato en la carretera o la basura abandonada cuando y donde no toca. Otro residente deja un reguero de salsas siempre que saca sus desechos. No tengo ubicado al disléxico, pero sí a quien tira un exceso de caldos desde la puerta de su casa. Me apetecería dejarle una notita recordándole que la escalera y su limpieza es responsabilidad de todos, pero me avergüenza firmar la misiva, no vaya a creer que soy la clásica metomentodo. Dejo la opción del anónimo para cuando me levante cobarde.
Una ventana al diseño desde Donostia y Pamplona noticiasdenavarra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from noticiasdenavarra.com Daily Mail and Mail on Sunday newspapers.
(0)
Yellowfin ranked first for Adaptability and categorized as an Innovative Vendor
MELBOURNE, Australia, April 22, 2021 /PRNewswire/ Yellowfin, the only analytics vendor that combines industry-leading action-based dashboards, automated discovery and data storytelling, today announced it has been ranked a Value Index Leader in Ventana Research s report, the 2021 Value Index for Analytics and Data.
The latest report evaluated the maturity of 18 software vendors, their products and value for enterprise use in analytics across seven evaluation categories. Technology vendors that score in the top three in any category earn the designation Value Index Leader. Yellowfin has done so in two of the categories: Adaptability and Manageability. The results have additionally categorized Yellowfin as an Innovative Vendor.
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.